Clinical Trials

90 enrolled 19 charts

Prostatic Neoplasms

NCT03660826 2026-04-13

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

288 enrolled 21 charts

Carcinosarcoma, Carcinoma, Endometrioid

NCT04739800 2026-04-13

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Phase 1/2 Active not recruiting

120 enrolled 19 charts

GenitourinaryGynecologic

Fallopian Tube Mucinous Adenocarcinoma

NCT01064648 2026-03-31

Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma

117 enrolled 23 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural

NCT02484404 2026-03-25

Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...

Phase 1/2 Active not recruiting

268 enrolled

BreastGastrointestinal

Breast Neoplasms, Colorectal Neoplasms

NCT01116648 2026-03-05

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

Phase 1/2 Active not recruiting

155 enrolled 34 charts

BreastGynecologic

Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms

NCT02345265 2026-03-05

Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer

70 enrolled 16 charts

Phase 3 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02446600 2026-03-05

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

579 enrolled 17 charts

Phase 2/3 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02502266 2026-03-05

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

582 enrolled 21 charts

Phase 1 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04090567 2026-03-05

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

Phase 2 Recruiting

60 enrolled

Breast

Breast Neoplasms

NCT00750841 2026-02-23

Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours

64 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT03851614 2026-02-09

DAPPER

90 enrolled

Leiomyosarcoma

NCT01391962 2026-02-02

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

34 enrolled 22 charts

Sarcoma, Alveolar Soft Part

NCT03334617 2025-10-27

HUDSON

528 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT02498613 2025-09-25

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

122 enrolled 16 charts

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02974621 2025-08-03

Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma

70 enrolled 15 charts

CNS

Glioblastoma

NCT00942877 2025-03-03

Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma

53 enrolled 17 charts

Sarcoma, Sarcoma, Alveolar Soft Part

NCT04487587 2025-02-26

COMICE

79 enrolled

Uterine Cervical Neoplasms

NCT03314740 2025-01-10

BAROCCO

123 enrolled 14 charts

Ovarian Neoplasms

NCT03117933 2024-01-23

OCTOVA

139 enrolled

Ovarian Neoplasms

NCT02899728 2023-10-17

Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer

Phase 2 Terminated

9 enrolled 4 charts

Extensive Stage Lung Small Cell Carcinoma

NCT00795340 2023-08-22

Cediranib, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 3 Completed

306 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00107250 2023-08-04

AZD2171 + Chemotherapy in Advanced NSCLC, Colorectal Cancer, or Other Cancer Suitable for Treatment With Capecitabine (Non-Small Lung Cancer Patients Closed to Enrollment as 8/9/07)

50 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00245154 2023-08-04

Paclitaxel + Carboplatin With/Out Cediranib Maleate in Stage III or Stage IV Non-Small Cell Lung Cancer

Phase 2/3 Completed

296 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00343408 2023-08-04

AZD2171 and Standard Combination Chemotherapy in Advanced Non-Small Cell Lung Cancer or Colorectal Cancer

31 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT03741426 2023-06-07

WIRE

Phase 2 Unknown

60 enrolled

Carcinoma, Renal Cell

NCT00662506 2023-06-06

Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

Phase 1/2 Completed

46 enrolled

CNSSarcoma

Glioblastoma, Gliosarcoma

NCT01160926 2023-04-24

DREAMtherapy

Phase 1 Terminated

31 enrolled

Gastrointestinal

Rectal Neoplasms

NCT03278717 2022-09-27

ICON9

Phase 3 Unknown

330 enrolled

Ovarian Neoplasms

NCT01062425 2022-07-26

Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma

261 enrolled 10 charts

CNSSarcoma

Glioblastoma, Gliosarcoma

NCT02681237 2022-05-09

A Study of Cediranib and Olaparib at Disease Worsening in Ovarian Cancer

Phase NA Completed

34 enrolled

Ovarian Neoplasms

NCT02889900 2022-03-08

CONCERTO

62 enrolled 15 charts

Phase EARLY_PHASE1 Completed

Ovarian Neoplasms

NCT03570437 2022-03-02

COPELIA

Phase 2 Unknown

124 enrolled

GynecologicSarcoma

Carcinosarcoma, Neoplasms, Endometrial Neoplasms

NCT02855697 2022-02-22

MOLTO

28 enrolled

Ovarian Neoplasms

NCT01208051 2021-07-15

Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer

Phase 1/2 Completed

127 enrolled 18 charts

EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid Cancer, Papillary, Adenocarcinoma, Follicular

NCT01065662 2021-04-21

AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies

11 enrolled

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT04184518 2020-06-02

CEDUVEAL-M

Phase 2 Withdrawn

Dermatologic

Uveal Melanoma, Neoplasm Metastasis

NCT00321581 2019-11-21

AZD2171 to Treat Children and Adolescents With Solid Tumors or Acute Myelogenous Leukemia

Other hematologic neoplasm

18 enrolled

Neoplasms, Leukemia, Myeloid, Acute

NCT01132820 2019-08-08

Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer

53 enrolled 11 charts

Endometrial Adenocarcinoma

NCT01337401 2019-01-24

CASPS

Phase 2 Unknown

36 enrolled

Sarcoma, Sarcoma, Alveolar Soft Part

NCT00436956 2018-10-09

AZD2171 to Treat Prostate Cancer

59 enrolled 12 charts

Prostatic Neoplasms

NCT00278343 2018-08-29

Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer

74 enrolled 11 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT00243061 2018-08-27

AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma

24 enrolled 12 charts

Dermatologic

Uveal Melanoma, Melanoma

NCT00527124 2018-08-09

Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Phase 2 Terminated

57 enrolled 12 charts

Prostatic Neoplasms

NCT01260688 2018-08-08

Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel

22 enrolled 23 charts

Prostatic Neoplasms

NCT02340611 2018-06-12

A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib

4 enrolled

Ovarian Neoplasms

NCT00410904 2018-04-13

AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung Cancer

60 enrolled 8 charts

Carcinoma, Non-Small-Cell Lung

NCT00243074 2018-01-23

S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery